The Penetration of Biosimilars in the US Will Vary Across Different

Biological Classes

The volume penetration of biosimilars in the US will strongly depend upon the

complexity of the molecule, the patient pool that it caters and the extent of savings

it brings to payers and providers

IMARC Group, one of the world’s leading life science research and advisory firms,

finds that as a result of their higher molecule complexity, higher cost of

manufacturing and lower number of biosimilar competitors (2-5 in case of

biosimilars as against up to 9-10 in small molecule generics); the average volume

penetration of biosimilars will be significantly lower than that of small molecule

generics. The study also expects the volume penetration of different biological

classes to vary from one another depending upon the following factors:

Biosimilars which are more complex will have a lower penetration compared to those

that are less complex.

Volume penetration would also depend upon how lucrative the branded biological drug

is for biosimilar volume erosion. Drugs that have achieved blockbuster sales and show a

good potential for future growth represent a good target for biosimilar companies. Payers

and Providers are also expected to promote biosimilars which enable them to achieve

substantial cost savings.

Trends of in-market biosimilars show that penetration rates also depend upon the

targeted indication and patient pool for biosimilar drugs. Drugs which are targeted

towards more sensitive patients (i.e. children) are expected to have a lower penetration

rate as physicians will not prescribe these drugs until they have significant long term

safety and efficacy data. Similarly, indications where the benefits and side effects of the

drug are not immediately visible and take a long time to identify (i.e. hormone deficiency)

will have a lower share than indications where the side effects and benefits are easily

visible (i.e. Anaemia).

The penetration of various biosimilars would vary across different countries. The volume

penetration of small molecule generics in the US has been found to be higher than that

imarc© 1

of major European markets. As a result, we expect biosimilar penetration in the US to be

higher than major European markets.

IMARC’s new report entitled “Biosimilar/Follow-on Biologics Market Report & Forecast:

A Focus on the US (2011-2020)” provides an analytical and statistical insight into the US

biosimilar market. The study, that has been undertaken using desk-based as well as

qualitative primary research, provides and draws upon analysis of six aspects of

the US biosimilar market.

Key Aspects Analyzed:

Evaluating the Current Market Landscape of Biosimilars:

Identification of currently marketed biosimilars and their historical performance

Identifying the reasons for the slow uptake of currently marketed biosimilars

Analyzing historical data to formulate conclusions on the future growth and market

trends of biosimilars

Evaluating the Extent of Price, Sales and Volume Erosions Caused by Biosimilars:

Analyzing historical time series data on price, volume and sales erosion in the US &

Europe

Analyzing previous models and assumptions on price and volume erosion caused by

biosimilars

Evaluating and comparing price and volume erosion created by biosimilars vis-a-vis by

small molecule generics

Evaluating and comparing price, volume and sales erosion by biosimilars across various

biological classes

Evaluating the Market Potential of Biosimilars Across Various Molecules:

Molecules Covered: Somatropin (Genotropin/Humatrope/Other HGH), Epoetin Alfa

(Epogen/Eprex), Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Insulin Lispro (Humalog),

Insulin Glargine (Lantus), Insulin Detemir (Levemir), Interferon Beta-1A (Avonex), Interferon

Beta-1A (Rebif), Interferon Beta-1B (Betaferon), Bevacizumab (Avastin), Trastuzumab

(Herceptin), Rituximab (Mabthera/Rituxan), Cetuximab (Erbitux), Etanercept (Enbrel), Infliximab

imarc© 2

(Remicade), Adalimumab (Humira), Ranibizumab (Lucentis), Omalizumab (Xolair) and

Natalizumab (Tysabri).

Focus of the Analysis for Each Molecule:

Historical background and overview

Historical brand sales

Patent position

Competing products

Biosimilars in pipeline

Brand and biosimilar sales forecasts

Evaluating the Sales of Biosimilars across Various Indications:

Indications Covered: Immunology & Inflammation, Diabetes, Oncology, Blood Disorders and

Growth Deficiency

Focus of the Analysis for Each Indication:

Historical brand sales

Brand and biosimilar sales forecasts

Indication wise breakup of molecules

Evaluating the Biosimilar Competitive Landscape:

Identifying branded biological manufacturers that expect the highest amount of erosion

from biosimilars

Identifying biosimilar manufacturers and their pipelines

Understanding the Current Legislation on Biosimilars:

An insight into the Biologics Price Competition and Innovation Act

An insight into the key biosimilar issues that still remain unaddressed

Interchangeability and Substitutability

Data Exclusivity

Statutory provisions for dealing with patent litigations

To buy the complete report or to get a free sample, please contact:

IMARC Group AsiaEmail: apac@imarcgroup.com

imarc© 3

Phone: +91-120-425-6531

IMARC Group North America Email:  america@imarcgroup.comPhone: +1-631-791-1145

To know more please visit: http://www.imarcgroup.com/

Key words

Biosimilar market, biosimilar industry, follow-on biologics market, biogenerics market, us biosimilar

market, biosimilar volume penetration rate

imarc© 4